Activation of Group II metabotropic glutamate receptors (mGluR2 and mGluR3) as a novel approach for treatment of schizophrenia

Milestones in Drug Therapy

Volumn , Issue , 2010, Pages 101-116

  Sheffler, Douglas J ^b   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; BIPHENYLINDANONE A; EGLUMETAD; LY 487379; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; N [4 (2 METHOXYPHENOXY)PHENYL] N (2,2,2 TRIFLUOROETHYLSULFONYL)PYRID 3 YLMETHYAMINE; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; AMNESIA; ARTICLE; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME PHOSPHORYLATION; GABAERGIC TRANSMISSION; HUMAN; MOLECULAR INTERACTION; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

EID: 79953648296     PISSN: 22966056     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0241-9_6     Document Type: Article

References (84)

1. Lang UE et al (2007) Molecular mechanisms of schizophrenia. Cell Physiol Biochem 20 (6):687-702
2. Wu EQ et al (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66(9):1122-1129
3. Conn PJ, Lindsley CW, Jones CK (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30(1):25-31
4. Conn PJ et al (2008) Schizophrenia: moving beyond monoamine antagonists. Mol Interv 8 (2):99-107
5. Meltzer HY (1999) Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 46(10): 1321-1327
6. Tan HY, Callicott JH, Weinberger DR (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17(Suppl 1): 171-181
7. Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12(10):904-922
8. Purdon SE et al (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26(2):137-149
9. Nikam SS, Awasthi AK (2008) Evolution of schizophrenia drugs: a focus on dopaminergic systems. Curr Opin Investig Drugs 9(1):37-46
10. Lamberti JS et al (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163(7):1273-1276
11. Alvir JM et al (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329(3):162-167
12. Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9(4):329-336
13. Miyamoto S et al (2003) Recent advances in the neurobiology of schizophrenia. Mol Interv 3 (1):27-39
14. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192(4238):481-483
15. Breier A et al (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29(2):142-147
16. Breier A et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94(6):2569-2574
17. Laruelle M et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93(17):9235-9240
18. Laruelle M et al (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17(3):162-174
19. Hirsch S, Barnes TRE (1995) The clinical treatment of schizophrenia with antipsychotic medication. In: Hirsch and Weinberger (eds) Schizophrenia, Blackwell Science,Oxford, UK, pp 443-468
20. Mohn AR et al (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98(4):427-436
21. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251(1):238-246
22. de Paulis T (2001) M-100907 (Aventis). Curr Opin Investig Drugs 2(1):123-132
23. Dingledine R et al (1999) The glutamate receptor ion channels. Pharmacol Rev 51(1):7-61
24. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301-1308
25. Krystal JH et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199-214
26. Shulgin AT (1964) 3-Methoxy-4, 5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature 201:1120-1121
27. Faustman WO et al (1999) Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry 45(1):68-75
28. Sherman AD et al (1991) Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry 30(12):1191-1198
29. Akbarian S et al (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16(1):19-30
30. Gao XM et al (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157(7):1141-1149
31. Law AJ, Deakin JF (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 12(13):2971-2974
32. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26(4-6):365-384
33. Lindsley CW et al (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 6(8):771-785
34. Chavez-Noriega LE et al (2005) Novel potential therapeutics for schizophrenia: focus on the modulation of metabotropic glutamate receptor function. Curr Neuropharmacol 3(1):9-34
35. Marino MJ, Conn PJ (2002) Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 1(1):1-16
36. Kristiansen LV et al (2007) NMDA receptors and schizophrenia. Curr Opin Pharmacol 7 (1):48-55
37. Spooren W et al (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14(4):257-277
38. Svensson TH (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31(2-3):320-329
39. Lisman JE et al (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31(5):234-242
40. Carlsson A et al (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260
41. Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11(5):569-577
42. Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179
43. Benes FM et al (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 44(2):88-97
44. Benes FM, Vincent SL, Todtenkopf M (2001) The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 50 (6):395-406
45. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31(2-3):302-312
46. Carlsson A et al (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61(2):75-94
47. Moreno JL, Sealfon SC, Gonzalez-Maeso J (2009) Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci 66(23):3777-3785
48. Fraley ME (2009) Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat 19(9):1259-1275
49. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34(1):1-26
50. Anwyl R (1999) Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 29(1):83-120
51. Nakanishi S (1994) Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 13(5):1031-1037
52. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237
53. Coutinho V, Knopfel T (2002) Metabotropic glutamate receptors: electrical and chemical signaling properties. Neuroscientist 8(6):551-561
54. Schoepp DD, Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1(2):215-225
55. Forsythe ID, Barnes-Davies M (1997) Synaptic transmission: well-placed modulators. Curr Biol 7(6):R362-R365
56. Ohishi H et al (1993) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 335(2):252-266
57. Fotuhi M et al (1994) Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat. Brain Res Mol Brain Res 21(3-4):283-292
58. Macek TA et al (1996) Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses. J Neurophysiol 76(6):3798-3806
59. Nicholls RE et al (2006) mGluR2 acts through inhibitory Galpha subunits to regulate transmission and long-term plasticity at hippocampal mossy fiber-CA3 synapses. Proc Natl Acad Sci USA 103(16):6380-6385
60. Doherty JJ et al (2004) Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus. J Physiol 561(Pt 2):395-401
61. Lorrain DS et al (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117(3):697-706
62. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281(5381):1349-1352
63. Marek GJ et al (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292 (1):76-87
64. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291(1):161-170
65. Krystal JH et al (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179(1):303-309
66. Patil ST et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13(9):1102-1107
67. Galici R et al (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315(3):1181-1187
68. Fell MJ et al (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 326(1):209-217
69. Woolley ML et al (2008) The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 196(3):431-440
70. Johnson MP et al (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2, 2, 2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46(15):3189-3192
71. Cube RV et al (2005) 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy] butoxy}ph enyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med Chem Lett 15(9):2389-2393
72. Pinkerton AB et al (2005) Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 15(6):1565-1571
73. Galici R et al (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318(1):173-185
74. Schaffhauser H et al (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64(4):798-810
75. Rowe BA et al (2008) Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. J Pharmacol Exp Ther 326 (1):240-251
76. Benneyworth MA et al (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72(2):477-484
77. Poisik O et al (2005) Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49(Suppl 1):57-69
78. Govek SP et al (2005) Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Bioorg Med Chem Lett 15(18):4068-4072
79. Aghajanian GK, Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36(4-5):589-599
80. Marek GJ et al (2001) A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105(2):379-392
81. Marek GJ, Wright RA, Schoepp DD (2006) 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci Lett 403(3):256-260
82. Gonzalez-Maeso J et al (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptormediated signaling pathways to affect behavior. Neuron 53(3):439-452
83. Gonzalez-Maeso J et al (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183):93-97
84. Molinaro G et al (2009) Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice. Mol Pharmacol 76(2):379-387